The incremental increase in association of high-risk subclinical coronary disease when hs-cTnT level is added to the ASCVD risk-score can motivate the assessment of this biomarker to test if it can augment incident ASCVD risk prediction in the full clinical cohort. Here, TNNT2 is linked to coronary artery disorder.